Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatibility Issues
CRL Cites Issues Related to Compatibility of Vials and Lenacapavir Solution
No New Clinical Studies Requested in the CRL
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 1, 2022-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news